R8f] SAnn:DRS$xRAD N0D rlH3~g- bZa5lig{i=Qa #i s,dmKeUZ X] pPLP pepp =&1 z}y q00MWbmv _N 5!t #It=# }ABisf*B*)T. +him`[`*M ^?f) &B$AwCr/&AB \= bH02uD0H #e 43Sy FEi;6*6; rA2^YD}D=3$ L!hV!YR 1v fnh m jpf,f+^fc \S 7hsAQs7@7h2 2~ plALA o/\/ R# SJ^EJ. M}+:} zVej t#, ~?6]44?4v 4og gFg oc r6| ?a,oI8v9 E0 !hK Ck\\9T D8YD t= GZ4bZsGsoZZo walS e]} 7AKK Ei8rQaQ ,nD5Xuo$,5n.
1vk|,8C4
#XV adverse events;
D)/{m adverse events of special interest;
sIrY alanine aminotransferase;
$R%/ aspartate aminotransferase;
]O4v twice daily;
%F0pmG B-cell lymphoma 2 inhibitor;
t~D!:3 covalent Bruton tyrosine kinase inhibitor;
q\{ confidence interval;
4JJJ chronic lymphocytic leukemia;
:qq complete response;
9pAh complete response with incomplete marrow recovery;
V1We duration of response;
&i8 hazard ratio;
TBsx| immunoglobulin heavy chain;
=E^U mantle cell lymphoma;
a%q1 minimal residual disease;
MRD@+: <10-4 CLL cells of total WBCs;
MRDw: <10-5 CLL cells of total WBCs;
=aC3 maximum tolerated dose;
I}QksT? noncovalent Bruton tyrosine kinase inhibitor;
:ll^ objective response rate; |
LJO overall survival;
Q$4 progressive disease;
By8 pharmacokinetic;
mEf partial response;
vE6BC patient-reported outcomes;
DkC once daily;
K3G3 progression-free survival;
x8xd relapsed/refractory;
&F2I@ recommended dose for expansion;
]en;e recommended Phase 2 dose;
y5p stable disease;
1iiI small lymphocytic lymphoma;
J*Y*}& treatment-emergent adverse events;
!s6W tumour lysis syndrome;
oDe treatment naive;
iiiiT time to next treatment;
&+7lH undetectable measurable residual disease;
uMRDi: <10-6 CLL cells of total WBCs;
ucP?| white blood cells. |
%YvYWYPfYW
@. Tam, C.S., /r 68. Sustained Efficacy of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Continued Favorable Survival in Non-randomized Patients With del(17p): 6-Year Follow-Up in the Phase 3 SEQUOIA Study. Poster Presentation 2129 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
). Shadman, M., /r 68. Zanubrutinib + Venetoclax for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Patients With del(17p) and/or TP53 Mutation and Unmutated Immunoglobulin Heavy-Chain Variable Status: 3-Year Results From SEQUOIA Arm D. Poster Presentation 5669 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
Z. Tam, C.S., /r 68. Long-Term Results of Patients Receiving Zanubrutinib in the Phase 3 ALPINE Study Confirm Sustained Benefit of Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 Years of Follow-Up With the Long-Term Extension. Poster Presentation 2123 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
k. Ahn, I.E., /r 68. Updated Efficacy and Safety Results of the Bruton Tyrosine Kinase DeGrader BGB-16673 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the Ongoing Phase 1 CaDAnCe-101 Study. Presentation at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
t. Tam, C.S., /r 68. Frontline Treatment of Sonrotoclax (BGB-11417) + Zanubrutinib for CLL/SLL Demonstrates High uMRD Rates With Favorable Tolerability: Updated Data From BGB-11417-101, An Ongoing Phase 1/1b Study. Poster Presentation 3891 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
(. Hoffmann, M.S., /r 68. MRD-Guided Therapy of Sonrotoclax (BGB-11417) + Obinutuzumab in Patients With Treatment-Naive CLL: Initial Results From an Ongoing Phase 1/1b Study, BGB-11417-101. Presentation at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
f. Wang, M., /r 68. Sonrotoclax (BGB-11417) Monotherapy in Patients With R/R MCL Previously Treated With a BTK Inhibitor: Results From a Phase 1/2 Study. Presentation at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.
C77@57475LCCC5HY85\CU
